Chlamydia trachomatis
Vaccines Forecast
Chlamydia trachomatis caused an estimated 128.5 million new infections worldwide in 2020, yet decades of vaccine research produced only early-stage candidates. That changed in March 2025, when Sanofi's mRNA candidate received FDA Fast Track designation and entered human trials, alongside Statens Serum Institut's CTH522 advancing toward dual urogenital and ocular Phase 2 testing. This is the independent commercial assessment of what a workable vaccine could be worth, drawing on VacZine Analytics' long-standing, independent authority in STD vaccine markets.
- Format
- PDF (>225 slides) + Excel
- Coverage
- 18 HIC + BRICM + GAVI (40)
- Vaccines assessed
- CTH522, Sanofi mRNA, Ziphius
- Profiles
- Urogenital + ocular (trachoma)
- Approach
- Scenario-based
- Base edition
- April 2025
- Availability
- Syndicated / bespoke
infections worldwide in 2020
aged 15 to 49 (WHO)
in new chlamydia cases
received FDA Fast Track status
Why Chlamydia has remained a vaccine priority for decades
Chlamydia trachomatis is one of the most common infections in humanity, and one whose consequences fall disproportionately on reproductive and ocular health. Understanding both the scale of that burden and why the field's most advanced candidates are only now reaching human trials is central to understanding what a workable vaccine could be worth.
Pathogen overview - Chlamydia trachomatis
Chlamydia trachomatis is a Gram-negative bacterium responsible for one of the most common sexually transmitted infections (STIs) worldwide, causing an estimated 128.5 million new infections in 2020 among adults aged 15 to 49. WHO estimates global prevalence in this age group at 4.0% in women and 2.5% in men. A separate 2021 modelling analysis estimated global incidence at 235.7 million cases and prevalence at 152.2 million, underscoring how widely burden estimates vary depending on methodology, and why WHO launched its first global database on STI prevalence in 2026 to help standardise the evidence base across 766 studies and more than 2,450 data points.
Although infection is mostly asymptomatic, in women untreated ascending infections can result in severe sexual and reproductive health outcomes, including pelvic inflammatory disease, ectopic pregnancy and infertility. Chlamydia infection also elevates the risk of HIV acquisition and transmission, and can cause neonatal conjunctivitis, itself a cause of blindness in newborns. In the developing world, ocular C. trachomatis infection causes trachoma, the leading cause of infectious blindness worldwide. Although chlamydia infections are generally treatable with antibiotics, the bacterium has a high rate of reinfection, driven by silent, asymptomatic carriage in younger populations, and WHO's Global Health Sector Strategy on HIV, Viral Hepatitis and STIs 2022 to 2030 sets a target of a 50% reduction in new chlamydia cases by 2030.
A prophylactic, chlamydia-specific vaccine that reduces infection or shortens disease course could meaningfully reduce these adverse outcomes and lower reliance on antibiotic treatment. Such a vaccine could be targeted routinely to adolescents and young adults, or to high-risk groups such as gay, bisexual and other men who have sex with men (GBMSM), who account for a disproportionate share of diagnoses, and could offer dual utility against both genital and ocular disease in developing-world settings.
The field has moved from decades of preclinical effort to a regulatory-backed human-trial programme within the past two years. Statens Serum Institut's CTH522, adjuvanted with CAF01 or CAF09b liposomes, completed a Phase 1 trial (CHLM-02, 65 participants enrolled 2020 to 2022, published in The Lancet Infectious Diseases in 2024) showing a favourable safety profile and robust neutralising antibody responses against both trachoma (serovar B) and urogenital (serovar D) strains, and it is now advancing toward Phase 2 testing of both indications. In March 2025, Sanofi's multi-antigen mRNA candidate received FDA Fast Track designation and entered a Phase 1/2 trial (adults aged 18 to 29, three intramuscular doses, 12 month follow-up), designed to protect against both primary infection and reinfection. Ziphius's self-amplifying RNA (saRNA) candidate remains preclinical, alongside earlier-stage academic programmes from Abera and the University of North Carolina School of Medicine.
From decades of preclinical effort to a regulatory-backed frontrunner
Chlamydia vaccine development has historically lagged far behind other STI programmes. That gap has narrowed sharply over the past two years, with two candidates now in active human testing and a regulatory designation that signals renewed institutional confidence in the field.
-
Statens Serum InstitutPhase 1 completeCTH522 Urogenital + ocular
A subunit vaccine adjuvanted with CAF01 or CAF09b liposomes (or aluminium hydroxide). The CHLM-02 Phase 1 trial (65 participants, 2020 to 2022) showed a favourable safety profile and robust neutralising antibody responses against both trachoma (serovar B) and urogenital (serovar D) strains, published in The Lancet Infectious Diseases in 2024. Now advancing toward Phase 2 testing of both indications. -
SanofiPhase 1/2, FDA Fast TrackMulti-antigen mRNA candidate
Received FDA Fast Track designation in March 2025. A Phase 1/2 trial in adults aged 18 to 29 is evaluating three intramuscular doses against placebo, with 12 months of follow-up, designed to protect against primary genital tract infection and reinfection. The trial's registered enrollment target was revised down from 1,560 to 80 participants on ClinicalTrials.gov (NCT06891417) in early November 2026; the trial remains listed as recruiting and the designation is unchanged. -
ZiphiusPreclinicalSelf-amplifying RNA (saRNA) candidate
An earlier-stage saRNA approach, part of a broader wave of nucleic-acid platforms being applied to chlamydia after decades of subunit-dominated research. -
Academic programmesPreclinicalAbera and UNC School of Medicine, among others
Earlier-stage academic and biotech programmes continue to broaden the field's antigen and platform diversity beyond the two candidates now in clinical testing.
Sanofi's FDA Fast Track designation marks a first for the chlamydia vaccine field: after decades in which CTH522 stood largely alone in early clinical testing, a major manufacturer now has a regulatory-backed programme moving through human trials. The underlying opportunity is exceptionally broad, spanning routine adolescent immunization, high-risk group targeting, and developing-world trachoma control. The VacZine Analytics model quantifies the commercial opportunity under multiple pipeline-progression scenarios across both vaccine profiles.
Six analytical layers - one commercial picture
The MarketVIEW Chlamydia trachomatis analysis spans disease burden, target-population rationale, the post-2025 competitor landscape and scenario-based revenue forecasting across 18 high-income nations, BRICM and GAVI-eligible markets.
Bottom-up modelling across 18 high-income nations, plus BRICM and GAVI-eligible markets (40 countries), public and private.
CTH522's Phase 1 data and Phase 2 plans, Sanofi's FDA Fast Tracked mRNA candidate, Ziphius's saRNA approach and academic programmes.
Commercial and clinical feasibility of urogenital and ocular (trachoma) vaccine profiles, including target population rationale.
Base, upside and conservative scenarios across public and private markets, adolescent/young adult and high-risk target groups.
Updated global STI burden estimates drawing on WHO's 2026 global prevalence database, and reproductive health/trachoma sequelae.
Uptake, pricing and clinical development feasibility across adolescent/young adult, GBMSM and developing-world trachoma programmes.
A glimpse of the commercial model
The table below shows a partial view of the target-population and scenario framework. Full revenue outputs, pricing assumptions and country-level data are in the licensed model.
| Target population | Geography | Market type | Vaccine profile | Revenue scenario |
|---|---|---|---|---|
| Adolescents / young adults (routine) | 18 high-income nations | Public + private | Urogenital | Modelled |
| GBMSM high-risk cohort | High-income nations | Private | Urogenital | Modelled |
| Developing-world trachoma programmes | BRICM + GAVI (40) | Public programme | Ocular | Modelled |
| ██████████ | █████ | ████ | ██████ | $██m (base) |
| ██████████ | █████ | ████ | ██████ | $██m (upside) |
| Total addressable - base | Global | All | All profiles | $███m |
What you receive
A comprehensive intelligence package combining a detailed executive presentation and a fully interactive forecast model, built for decision-makers who need the full picture on the Chlamydia trachomatis vaccine opportunity.
- Executive presentation (>225 slides, PDF) - disease background, epidemiology, competitor pipeline, target population rationale and full commercial assessment with supporting narrative and references
- Interactive MS-Excel forecast model (150 worksheets) - scenario-based volume and revenue outputs across 18 high-income nations, BRICM and GAVI-eligible markets
- Scenario-based commercial forecasts - base, upside and conservative cases reflecting the post-2025 pipeline inflection
- Competitor intelligence - CTH522 (Statens Serum Institut), Sanofi's FDA Fast Tracked mRNA candidate, Ziphius saRNA, and academic programmes
- Updated epidemiology module - global STI burden drawing on WHO's 2026 global prevalence database, reproductive health sequelae, and trachoma blindness data
- Target population & access assessment - uptake, pricing and clinical development feasibility across urogenital and ocular vaccine profiles
Built for organisations weighing the Chlamydia opportunity
Most valuable to teams evaluating the Chlamydia trachomatis vaccine market against their own pipeline, BD ambitions or investment thesis, particularly in light of Sanofi's 2025 Fast Track designation and CTH522's advance toward Phase 2.
Vaccine developers
Positioning, commercial feasibility and target-population prioritisation for chlamydia candidates at any stage.
Corporate strategy & BD
Validate the market size and structure now that a major manufacturer has entered clinical development.
Investors & analysts
Independent assessment of market size and pipeline risk for due diligence on chlamydia and adjacent STD vaccine assets.
Public health & global health programmes
Demand modelling for sexual health, adolescent immunization and developing-world trachoma control programmes.
Researchers & academia
Comprehensive epidemiology and vaccine landscape for grant and translational planning, including CTH522 and mRNA platform data.
Market access & policy
Pricing benchmarks and access-pathway assumptions across public and private sexual health and global health channels.
VacZine Analytics has tracked STD vaccine markets since our earliest editions, positioning us to reassess the Chlamydia trachomatis opportunity the moment the pipeline changed. This analysis combines a rigorous epidemiological and clinical review with an independently constructed commercial model spanning 18 high-income nations, BRICM and GAVI-eligible markets that most forecasts model only in aggregate. Few groups have followed this market as closely or for as long, and that recognised, independent expertise underpins everything in the analysis, which has been well received by clients across the field.
This April 2025 edition incorporates Sanofi's March 2025 FDA Fast Track designation and Phase 1/2 trial start, alongside CTH522's published Phase 1 data and Phase 2 plans. The full syndicated MarketVIEW edition proceeds subject to sufficient client buy-in; where a faster or more tailored answer is required, VacZine Analytics can also be commissioned to deliver bespoke, ad-hoc analysis on this market.
Syndicate the refresh - or commission the answer you need
Register your interest to help shape and secure a full syndicated MarketVIEW refresh, which proceeds subject to sufficient client buy-in. Single-licence and multi-user options follow on publication. Need something faster or more specific? VacZine Analytics can be commissioned for bespoke, ad-hoc Chlamydia analysis, a briefing call is included on request.